You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tyrosine kinase inhibitor resistance

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Innate CD8+ T Cells and Evolution of Tyrosine Kinase Inhibitor

Recruiting
  • Leukemia
  • +3 more
  • Phenotyping of total and innate CD8+T cells by flow cytometry
  • Nîmes, Gard, France
    CHU de Nîmes
Jul 19, 2021

Resistance to Tyrosine Kinase Inhibitor Osimertinib and

Recruiting
  • Lung Cancer
  • Blood Samples
  • Lorient, France
  • +3 more
Apr 26, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Rotterdam, Netherlands
      Erasmus MC
    Feb 2, 2022

    Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

    Recruiting
    • Liver Neoplasms
    • Tislelizumab plus tyrosine kinase inhibitor
    • Beijing, Beijing, China
      302 Hospital
    Sep 22, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

    Completed
    • Gastrointestinal Stromal Tumors (GISTs)
    • Imatinib Mesylate
    • Seoul, Korea, Republic of
      Asan Medical Center
    Dec 30, 2022

    CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

    Recruiting
    • CML
    • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
    • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
      FUNDALEU
    Jun 29, 2023

    Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

    Recruiting
    • Lung Neoplasms
    • +23 more
    • La Jolla, California
    • +35 more
    Oct 6, 2022

    Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    Nov 28, 2022

    Breast Cancer Trial in Guangzhou (Take probiotics)

    Recruiting
    • Breast Cancer
    • Take probiotics
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Mar 6, 2023

    Multiple Sclerosis Trial run by the National Institute of Neurological Disorders and Stroke (NINDS) (tolebrutinib 60mg,

    Active, not recruiting
    • Multiple Sclerosis
    • tolebrutinib 60mg
    • tolebrutinib 120mg
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • Chronic Lymphocytic Leukemia
    • East Melbourne, Victoria, Australia
    • +7 more
    Jan 20, 2023

    Metabolic Alternation and Clinicohematological Characteristic in

    Not yet recruiting
    • CML, Chronic Phase
    • Tyrosine kinase inhibitor
    • (no location specified)
    Nov 6, 2023

    Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia

    Not yet recruiting
    • Tyrosine Kinase Inhibitor
    • +2 more
      • Taipei, Taiwan
        National Taiwan University Hospital
      Feb 17, 2022

      Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)

      Recruiting
      • Acute Lymphoblastic Leukemia
      • Philadelphia Chromosome-Positive
      • Blinatumomab
      • +3 more
      • New York, New York
      • +1 more
      Nov 10, 2022

      High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

      Recruiting
      • High-Risk Localized Soft Tissue Sarcoma
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Apr 20, 2023

      HRQOL in Locally Advanced Thyroid Carcinoma

      Recruiting
      • Thyroid Cancer
      • +2 more
      • Tyrosine kinase inhibitor drugs.
      • Fuzhou, Fujian, China
        Road Fuma No.420
      Apr 11, 2023

      Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

      Active, not recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • +2 more
      • Duarte, California
      • +14 more
      Jan 27, 2023

      Liposarcoma, Metastatic Liposarcoma Trial in Boston, Saint Louis, New York (MGCD516)

      Active, not recruiting
      • Liposarcoma
      • Metastatic Liposarcoma
      • Boston, Massachusetts
      • +2 more
      Nov 23, 2022

      Chronic Leukemia Trial in France (Additional biological samples)

      Active, not recruiting
      • Chronic Leukemia
      • Additional biological samples
      • Besançon, France
      • +3 more
      May 31, 2022

      Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

      Recruiting
      • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
      • Houston, Texas
        M D Anderson Cancer Center
      Feb 1, 2022

      CNS Lymphoma Trial in Petah Tikva (Imbruvica)

      Recruiting
      • Central Nervous System Lymphoma
      • Petah Tikva, Israel
        Hematology Institute
      May 9, 2022